

Piotr Adrian Klimiuk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8836011/publications.pdf>

Version: 2024-02-01

44
papers

2,122
citations

279798

23
h-index

315739

38
g-index

44
all docs

44
docs citations

44
times ranked

2602
citing authors

#	ARTICLE	IF	CITATIONS
1	T Cell Activation in Rheumatoid Synovium Is B Cell Dependent. <i>Journal of Immunology</i> , 2001, 167, 4710-4718.	0.8	443
2	Aldehyde reductase functions as a detoxification system for lipid peroxidation products in vasculitis. <i>Journal of Clinical Investigation</i> , 1999, 103, 1007-1013.	8.2	187
3	Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 804-809.	0.9	117
4	Central Role of Thrombospondin-1 in the Activation and Clonal Expansion of Inflammatory T Cells. <i>Journal of Immunology</i> , 2000, 164, 2947-2954.	0.8	109
5	Production of Cytokines and Metalloproteinases in Rheumatoid Synovitis Is T Cell Dependent. <i>Clinical Immunology</i> , 1999, 90, 65-78.	3.2	107
6	Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. <i>Seminars in Immunopathology</i> , 1998, 20, 5-22.	4.0	106
7	Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. <i>Clinical Rheumatology</i> , 2005, 24, 111-116.	2.2	105
8	Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212245.	0.9	88
9	Synoviocyte-Mediated Expansion of Inflammatory T Cells in Rheumatoid Synovitis Is Dependent on CD47-Thrombospondin 1 Interaction. <i>Journal of Immunology</i> , 2003, 171, 1732-1740.	0.8	63
10	Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. <i>Rheumatology</i> , 2002, 41, 78-87.	1.9	56
11	Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 472-475.	0.9	56
12	Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 1523-9.	2.0	51
13	Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 179-185.	2.3	50
14	Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 238-42.	2.0	45
15	Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2007, 36, 345-350.	1.1	44
16	The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 685-690.	2.2	42
17	A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2006, 25, 314-319.	2.2	41
18	Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate. <i>Advances in Medical Sciences</i> , 2016, 61, 193-197.	2.1	41

#	ARTICLE	IF	CITATIONS
19	Association between type 1 diabetes and periodontal health. <i>Advances in Medical Sciences</i> , 2014, 59, 126-131.	2.1	39
20	Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1666-72.	2.0	39
21	Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 38-45.	1.1	35
22	Circulating intercellular adhesion molecule 1 in rheumatoid arthritis – Relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. <i>Clinical Rheumatology</i> , 1996, 15, 367-373.	2.2	30
23	Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2010, 29, 175-180.	2.2	29
24	Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Scandinavian Journal of Rheumatology, 2009, 38, 439-444.	1.1	22
25	Serum chemokines in patients with rheumatoid arthritis treated with etanercept. <i>Rheumatology International</i> , 2011, 31, 457-461.	3.0	22
26	Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1097-1105.	3.1	21
27	Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 1307-13.	2.0	21
28	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	3.5	18
29	Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2004, 52, 36-42.	2.3	18
30	The influence of Multiwave Locked System (MLS) laser therapy on clinical features, microcirculatory abnormalities and selected modulators of angiogenesis in patients with Raynaud's phenomenon. <i>Clinical Rheumatology</i> , 2015, 34, 489-496.	2.2	13
31	Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers. <i>Rheumatology International</i> , 2015, 35, 749-755.	3.0	12
32	Endothelial dysfunction in Graves' disease. <i>Advances in Medical Sciences</i> , 2013, 58, 31-37.	2.1	10
33	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1385-1395.	1.9	10
34	Intraoperative bleeding during endoscopic sinus surgery and microvascular density of the nasal mucosa. <i>Advances in Medical Sciences</i> , 2014, 59, 132-135.	2.1	9
35	The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 17-21.	2.2	8
36	Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE-RL). <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 545-548.	5.0	8

#	ARTICLE	IF	CITATIONS
37	Evaluation of foot static disturbances in patients with rheumatic diseases. <i>Reumatologia</i> , 2017, 55, 73-78.	1.1	5
38	Assessment of the efficacy of laser biostimulation and low-frequency pulsed magnetic field in the treatment of microvascular abnormalities in patients with Raynaud's phenomenon. <i>Reumatologia</i> , 2012, 5, 410-415.	1.1	1
39	FRIO189...Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra). , 2017, , .		1
40	AB0121...Changes of Glycosylation of Immunoglobulin G in Rheumatoid Arthritis Patients Treated with Methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 844.1-844.	0.9	0
41	THU0557...Nailfold Videocapillaroscopic Abnormalities and Selected Angiogenesis Modulators in Patients with Raynaud's Phenomenon after Multiwave Locked System (MLS) Laser Therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 375.2-375.	0.9	0
42	AB0447...Regulation of Serum Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases-1 following Rituximab Therapy in Patients with Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Blockers. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 956.1-956.	0.9	0
43	AB0675...Correlation Between Microvascular Abnormalities in Videocapillaroscopy and Angiogenesis Modulators in Patients with Raynaud's Phenomenon Before and After Multiwave Locked System (MLS) Laser Therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124.1-1124.	0.9	0
44	AB1095-HPR...Evaluation of The Static Foot Function in Patients with Reduced Mobility in The Course of Rheumatic Diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1306.2-1306.	0.9	0